Gender and androgen treatment influence the expression of proto- oncogenes and apoptotic factors in lacrimal and salivary tissues of MRL/lpr mice

Clinical Immunology and Immunopathology

Volumn 86, Issue 1, 1998, Pages 59-71

  Toda, Ikuko ^a   Wickham, L Alexandra ^a   Sullivan, David A ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

Apoptosis; Autoimmunity; Immunomodulators; mRNA; Oncogenes

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CYCLOPHOSPHAMIDE; FAS LIGAND; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRY EYE; FEMALE; GENE EXPRESSION REGULATION; IMMUNOMODULATION; IMMUNOPATHOGENESIS; LACRIMAL GLAND; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTO ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALIVARY GLAND; SEX DIFFERENCE; SJOEGREN SYNDROME;

EID: 0031963334     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1997.4466     Document Type: Article

References (76)

1. Homma M., Sugai S., Tojo T., Miyasaka N., Akizuki M. Sjögren's Syndrome. State of the Art, 1994;Kugler Press, Amsterdam.
2. Sullivan D. A. Possible mechanisms involved in the reduced tear secretion in Sjögren's syndrome. Sjögren's Syndrome. State of the Art. 1994;Kugler Press, Amsterdam. p. 13-19.
3. Fox R. I., Saito I. Sjögren's syndrome: Immunologic and neuroendocrine mechanisms. Adv. Exp. Med. Biol. 350:1994;609-621.
4. Whitcher J. P. Clinical diagnosis of the dry eye. Int. Ophthalmol. Clin. 27:1987;7-24.
5. Lamberts D. W. Keratoconjunctivitis sicca. Smolin G., Thoft R. A. The Cornea. Scientific Foundations and Clinical Practice. 1983;293-308 Little, Brown, Boston.
6. Ahmed S. A., Talal N. Sex hormones and the immune system-part 2. Animal data. Bailliere's Clin. Rheum. 4:1990;13-31.
7. Homo-Delarche F., Fitzpatrick F., Christeff N., Nunez E. A., Bach J. F., Dardenne M. Sex steroids, glucocorticoids, stress and autoimmunity. J. Ster. Biochem. Mol. Biol. 40:1991;619-637.
8. Ahmed S. A., Talal N. Importance of sex hormones in systemic lupus erythematosus. Wallace D., Hahn B. Dubois' Lupus Erythematosus. 1993;148-156 Lea and Febiger, Philadelphia.
9. Carlsten H., Tarkowski A., Holmdahl R., Nilsson L. A. Oestrogen is a potent disease accelerator in SLE-prone MRLlpr/lpr. Clin. Exp. Immunol. 80:1990;467-473.
10. Ahmed S. A., Aufdemorte T. B., Chen J. R., Montoya A. I., Olive D., Talal N. Estrogen induces the development of autoantibodies and promotes salivary gland lymphoid infiltrates in normal mice. J. Autoimmun. 2:1989;543-552.
11. Watanabe-Fukunaga R., Brannan C. I., Copeland N. G., Jenkins N. A., Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 356:1992;314-317.
12. Watanabe-Fukunaga R., Brannan C. I., Itoh N., Yonehara S., Copeland N. G., Jenkins N., Nagata S. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J. Immunol. 148:1992;1274-1279.
13. Adachi M., Watanabe-Fukunaga R., Nagata S. Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene oflpr. Proc. Natl. Acad. Sci. USA. 90:1993;1756-1760.
14. Chu J. L., Drappa J., Parnassa A., Elkon K. The defect in Fas mRNA expression in MRL/lpr. J. Exp. Med. 178:1993;723-730.
15. ++lpr/lpr. Proc. Natl. Acad. Sci. USA. 90:1993;10340-10344.
16. +. J. Immunol. 151:1993;7233-7239.
17. Wu J., Zhou T., Zhang J., He J., Gause W. C., Mountz J. D. Correction of accelerated autimmune disease by early replacement of the mutatedlprlpr/lpr. Proc. Acad. Natl. Sci. USA. 91:1994;2344-2348.
18. Mountz J. D., Steinberg A. D., Klinman D. M., Smith H. R., Mushinski J. F. Autoimunity and increased c-myb transcription. Science. 226:1984;1087-1089.
19. Mountz J. D., Steinberg A. D. Studies of c-myb gene regulation in MRL-lpr/lprlpr-lpr. J. Immunol. 142:1989;328-335.
20. Kitajima T., Furukawa F., Kanauchi H., Imamura S., Ogawa K., Sugiyama T. Histological detection of c-myb and c-myc proto-oncogene expression in infiltrating cells in cutaneous lupus erythematosus-like lesions of MRL/l mice byin situ. Clin. Immunol. Immunopathol. 62:1992;119-123.
21. Skopouli F. N., Kousvelari E. E., Mertz P., Jaffe E. S., Fox P. C., Moutsopoulos H. M. c-myc mRNA expression in minor salivary glands of patients with Sjögren's Syndrome. J. Rheumatol. 19:1992;693-696.
22. Sugai S., Saito I., Masaki Y., Takeshita S., Shimizu S., Tachibana J., Miyasaka N. Rearrangement of the rheumatoid factor-related germline gene Vg and bcl-2 expression in lymphoproliferative disorders in patients with Sjögren's Syndrome. Clin. Immunol. Immunopathol. 72:1994;181-186.
23. Watanabe D., Suda T., Hashimoto H., Nagata S. Constitutive activation of the Fas ligand gene in mouse lymphoproliferative disorders. EMBO J. 14:1995;12-18.
24. Chu J. L., Ramos P., Rosendorff A., Nikolic-Zugic J., Lacy E., Matsuzawa A., Elkon K. B. Massive upregulation of the Fas ligand inlprgld. J. Exp. Med. 181:1995;393-398.
25. Takahashi T., Tanaka M., Brannan C. I., Jenkins N. A., Copeland N. G., Suda T., Nagata S. Generalized lymphoproliferative disease in mice, caused by point mutation in the Fas ligand. Cell. 76:1994;969-976.
26. Alderson M. R., Armitage R. J., Maraskovsky E., Tough T. W., Roux E., Schooley K., Ramsdell F., Lynch D. H. Fas tranduces activation signals in normal human T lymphocytes. J. Exp. Med. 178:1993;2231-2235.
27. Sibbitt W. L. Oncogenes, growth factors and autoimmune diseases. Anticancer Res. 11:1991;97-113.
28. Kahan A., Gerfaux J., Kahan A., Joret A. M., Menkes C. J., Amor B. Increased proto-oncogene expression in peripheral blood T lymphocytes from patients with systemic sclerosis. Arthritis Rheum. 32:1989;430-436.
29. Souza L. M., Baluda M. A. Identification of the avian myeloblastosis virus genome. 1. Identification of restriction endonuclease fragments associated with acute myeloblastic leukemia. J. Virol. 36:1980;317-324.
30. Thompson C. B., Challoner P. B., Neiman P. E., Groudine M. Expression of the c-myb proto-oncogene during cellular proliferation. Nature. 319:1986;374-380.
31. Shi Y., Glynn J. M., Guilbert L. J., Cotter T. G., Bissonnette R. P., Green D. R. Role for c-myc activation-induced apoptotic cell death in T cell hybridomas. Science. 257:1992;212-214.
32. Bissonnette R. P., Echeverri F., Mahboubi A., Green D. R. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature. 359:1992;552-555.
33. Ryan J. J., Prochownik E., Gottlieb C. A., Apel I. J., Merino R., Nunez G., Clarke M. F. c-myc and bcl-2 modelate p53 function by altering p53 subcellular trafficking during the cell cycle. Proc. Natl. Acad. Sci. USA. 91:1994;5878-5882.
34. Hermeking H., Eick D. Mediation of c-myc-induced apoptosis by p53. Science. 265:1994;2091-2093.
35. Harrington E. A., Bennett M. R., Fanidi A., Evan G. I. c-myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J. 13:1994;3286-3295.
36. Ohsako S., Hara M., Harigai M., Fukasawa C., Kashiwazaki S. Expression and function of Fas antigen and bcl-2 in human systemic lupus erythematosus lymphocytes. Clin. Immunol. Immunopathol. 73:1994;109-114.
37. Gatenby P. A., Irvine M. The bcl-2 proto-oncogene is overexpressed in systemic lupus erythematosus. J. Autoimmunity. 7:1994;623-631.
38. Hockenbery D. M., Zutter M., Hickey W., Nahm M., Korsmeyer S. J. Bcl2 protein is topographically resticted in tissue characterized by apoptotic cell death. Proc. Natl. Acad. Sci. USA. 88:1991;6961-6965.
39. Tsujimoto Y., Croce C. M. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc. Natl. Acad. Sci. USA. 83:1986;5214-5218.
40. Nunez G., London L., Hockenbery D., Alexander M., McKearn J. P., Korsmeyer S. J. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J. Immunol. 144:1990;3602-3610.
41. Memon S. A., Moreno M. B., Petrak D., Zacharchuk C. M. Bcl-2 blocks glucocorticoid- but not fas- or activation-induced apoptosis in a T cell hybridoma. J. Immunol. 155:1995;4644-4652.
42. Kamada S., Shimono A., Yoshitaka S., Tsujimura T., Takahashi T., Noda T., Kitamura Y., Kondoh H., Tsujimoto Y. bcl-2 deficiency in mice leads to pleiotropic abnormalities: Accelerated lymphoid cell death in thymus and spleen, polycystic kidney, hair hypopigmentation, and distorted small intestine. Cancer Res. 55:1995;354-359.
43. Oltvai Z. N., Milliman C. L., Korsmeyer S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 74:1993;609-619.
44. Sato E. H., Sullivan D. A. Comparative influence of steroid hormones and immunosuppressive agents on autoimmune expression in lacrimal glands of a female mouse model of Sjögren's syndrome. Invest. Ophthalmol. Vis. Sci. 35:1994;2632-2642.
45. Clark J. H., Schrader W. T., O'Malley B. W. Mechanisms of action of steroid hormones. Wilson J. D., Foster D. W. Williams Textbook of Endocrinology. 1992;35-90 Saunders, Philadelphia.
46. Berchem G. J., Bosseler M., Sugars L. Y., Voeller H. J., Zeitlin S., Gelmann E. P. Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res. 55:1995;735-738.
47. Lu P. J., Lu Q. L., Rughetti A., Taylor-Papadimitriou J. bcl-2 overexpression inhibits cell death and promotes the morphogenesis, but not tumorogenesis of human mammary epithelial cells. J. Cell Biol. 129:1995;1363-1378.
48. Quarmby V. E., Beckman W. C. Jr., Wilson E. M., French F. S. Androgen regulation of c-myc messenger ribonucleic acid levels in rat ventral prostate. Mol. Endocrinol. 1:1987;865-874.
49. Smith H. R., Chused T. M., Steinberg A. D. Cyclophosphamide-induced changes in the MRL-lpr/lpr. Clin. Immunol. Immunopathol. 30:1984;51-61.
50. Mountz J. D., Mushinski J. F., Smith H. R., Klinman D. M., Steinberg A. D. Modulation of c-myb transcription in autoimmune disease by cyclophosphamide. J. Immunol. 135:1985;2417-2422.
51. Finlay C. A., Hinds P. W., Levine A. J. The p53 proto-oncogene can act as a suppressor of transformation. Cell. 57:1989;1083-1093.
52. Kitagawa M., Yoshida S., Kuwata T., Tanizawa T., Kamiyama R. p53 expression in myeloid cells of myelodysplastic syndromes. Am. J. Pathol. 145:1994;338-344.
53. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
54. Lai K. N., Ho R. T. H., Leung J. C. K., Chui Y. L., Lim P. L., Lui S. F., Li P. K. T. CD4-positive cells from patients with IgA nephropathy demonstrate increased mRNA of cytokines that induce the IgA switch and differentiation. J. Pathol. 174:1994;13-22.
55. Krajewski S., Krajewska M., Shabaik A., Miyashita T., Wang H. G., Reed J. C. Immunohistochemical detection of in vivo distribution of Bax, a domminant inhibitor of Bcl-2. Am. J. Pathol. 145:1994;1323-1336.
56. Munakata S., Hendricks J. B. Effect of fixtation time and microwave oven heating time on retrieval of the Ki-67 antigen from paraffin-embedded tissue. J. Histochem. Cytochem. 41:1993;1241-1246.
57. Chen S. J., Li H., Durand J., Oparil S., Chen Y. F. Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation. 93:1996;577-584.
58. Rocha F. J., Wickham L. A., Pena J. D. O., Gao J., Ono M., Lambert R. W., Kelleher R. S., Sullivan D. A. Influence of gender and the endocrine environment on the distribution of androgen receptors in the lacrimal gland. J. Ster. Biochem. Mol. Biol. 46:1993;737-749.
59. Pena J. D. O., Wickham L. A., Gao J., Ono M., Yoshino K., Sullivan D. A. Identification of androgen receptor mRNA in lacrimal tissues of rats and humans. Invest. Ophthalmol. Vis. Sci. Suppl. 35:1994;1826.
60. Sullivan D. A., Block L., Pena J. D. O. Influence of androgens and pituitary hormones on the structural profile and secretory activity of the lacrimal gland. Acta Ophthalmol. Scand. 74:1996;421-435.
61. Skarstein K., Jonsson R. The apoptosis related APO-1/FaslprFas. Clin. Rheum. Suppl. 14:1995;27.
62. Musgrove E. A., Lee C. S., Sutherland R. L. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol. Cell. Biol. 11:1991;5032-5043.
63. Teixeira C., Reed J. C., Pratt M. A. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res. 55:1995;3902-3907.
64. Chien C. H., Wang F. F., Hamilton T. C. Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells. Mol. Cell. Endocrinol. 99:1994;11-19.
65. Murphy L. J., Murphy L. C., Friesen H. G. Estrogen induction of N-myc and c-myc proto-oncogene expression in the rat uterus. Endocrinology. 120:1987;1882-1888.
66. Sullivan D. A., Sato E. H. Potential therapeutic approach for the hormonal treatment of lacrimal gland dysfunction in Sjögren's syndrome. Clin. Immunol. Immunopath. 64:1992;9-16.
67. Wickham, L. A. Gao, J. Krenzer, K. L. da Silveira, L. A. Rocha, E. M. Toda, I. Sullivan, D. A. Endocrine regulation of sex steroid receptors in the lacrimal gland, 1997.
68. Ariga H., Edwards J., Sullivan D. A. Androgen control of autoimmune expression in lacrimal glands of MRL/Mp-lpr/lpr. Clin. Immunol. Immunopathol. 53:1989;499-508.
69. Sullivan D. A., Edwards J. Androgen stimulation of lacrimal gland function in mouse models of Sjögren's syndrome. J. Steroid Biochem. Mol. Biol. 60:1997;237-245.
70. Rocha F. J., Sato E. H., Sullivan B. D., Sullivan D. A. Effect of androgen analogue treatment and androgen withdrawal on lacrimal gland inflammation in a mouse model (MRL/Mp-lpr/lpr. Reg. Immunol. 6:1994;270-277.
71. Ono M., Rocha F. J., Sullivan D. A. Immunocytochemical location and hormonal control of androgen receptors in lacrimal tissues of the female MRL/Mp-lpr/lpr. Exp. Eye Res. 61:1995;659-666.
72. Huang Z., Gao J., Wickham L. A., Sullivan D. A. Influence of gender and androgen treatment on TGF-β1 mRNA levels in the rat lacrimal gland. Invest. Ophthalmol. Vis. Sci. 35:1995;S991.
73. Wickham L. A., Huang Z., Sullivan D. A. Analysis of the androgen regulation of cytokine levels in the lacrimal gland: Evaluation of various methods. Invest. Ophthalmol. Vis. Sci. Suppl. 37:1996;S857.
74. Rocha E. M., Toda I., Wickham L. A., da Silveira L. A., Sullivan D. A. Influence of gender, androgens and cyclophosphamide on cytokine mRNA levels in lacrimal tissue of a mouse model of Sjögren's syndrome. Invest. Ophthalmol. Vis. Sci. Suppl. 38:1997;S443.
75. Vendramini A. C., Soo C. H., Sullivan D. A. Testosterone-induced suppression of autoimmune disease in lacrimal tissue of a mouse model (NZB/NZW F1) of Sjögren's syndrome. Invest. Ophthalmol. Vis. Sci. 32:1991;3002-3006.
76. Yin X. M., Oltvai Z. N., Korsmeyer S. J. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature. 369:1994;321-323.